Data of 38 patients were analyzed, 73.7% female. Mean age was 36.2 years-old. The mean number of antiepileptic drugs (AEDs) used was 8.9 for previous use and 2.5 for current use. 90% of patients had been previously exposed to levetiracetam (LEV). Mean seizure frequency in the last 3 months was 12 seizures per month. At 3, 6 and 12 months, the 50% responder rates were 44.1%, 36.4% and 58.37% while 14.7%, 18.2% and 16.7% were seizure free. No differences in efficacy were observed between generalized or focal epilepsy. Patients took BRV for a mean duration of 11.1 months. Retention rate was 55.3%. Reasons for discontinuation were adverse events (AEs) in 52.3%, lack of efficacy in 35.3% and both in 11.8%. The total AEs rate was 60.5% according to medical records and 85.7% according to questionnaire. The most frequent AEs were tiredness/sleepiness, psychiatric side effects and memory problems. Although not statistically significant, there was a trend which suggested that psychiatric AEs were more common among patients with psychiatric comorbidity. One patient developed frank psychosis 4 weeks into treatment.